- Home
- BGI vs PASG Comparison
BGI vs PASG Comparison
Compare BGI & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGI
- PASG
- Stock Information
- Founded
- BGI 1879
- PASG 2017
- Country
- BGI Canada
- PASG United States
- Employees
- BGI N/A
- PASG N/A
- Industry
- BGI
- PASG Biotechnology: Pharmaceutical Preparations
- Sector
- BGI
- PASG Health Care
- Exchange
- BGI Nasdaq
- PASG Nasdaq
- Market Cap
- BGI 22.7M
- PASG 25.9M
- IPO Year
- BGI 2005
- PASG 2020
- Fundamental
- Price
- BGI $1.15
- PASG $7.91
- Analyst Decision
- BGI
- PASG Strong Buy
- Analyst Count
- BGI 0
- PASG 4
- Target Price
- BGI N/A
- PASG $59.25
- AVG Volume (30 Days)
- BGI 3.3M
- PASG 39.8K
- Earning Date
- BGI 11-26-2025
- PASG 11-12-2025
- Dividend Yield
- BGI N/A
- PASG N/A
- EPS Growth
- BGI N/A
- PASG N/A
- EPS
- BGI N/A
- PASG N/A
- Revenue
- BGI $124,446,731.00
- PASG N/A
- Revenue This Year
- BGI N/A
- PASG N/A
- Revenue Next Year
- BGI N/A
- PASG N/A
- P/E Ratio
- BGI N/A
- PASG N/A
- Revenue Growth
- BGI N/A
- PASG N/A
- 52 Week Low
- BGI $0.56
- PASG $5.12
- 52 Week High
- BGI $2.31
- PASG $26.60
- Technical
- Relative Strength Index (RSI)
- BGI 61.02
- PASG 61.62
- Support Level
- BGI $1.00
- PASG $7.93
- Resistance Level
- BGI $1.23
- PASG $8.20
- Average True Range (ATR)
- BGI 0.12
- PASG 0.40
- MACD
- BGI -0.01
- PASG -0.01
- Stochastic Oscillator
- BGI 41.59
- PASG 56.08
About BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.